{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-26-000377","form_type":"8-K","ticker":"LCTC","cik":"0001493137","company_name":"Lifeloc Technologies, Inc","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.215132+00:00","generated_at":"2026-05-15T08:36:34.197101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lifeloc FY 2025 revenue up 6% to $9.027M; net loss widens to $2.47M on deferred tax charge","bullets":["Revenue $9.027M (+6% YoY); net loss $2.470M ($0.90/diluted share) vs $1.053M loss in 2024.","Gross margin stable at 40.3%; pre-tax loss improved to $1.311M from $1.405M.","Deferred tax valuation allowance increased to $1.738M (non-cash) from $187K.","SpinDetect drug analyzer: production mold fabrication started Q1 2026; first articles expected April.","New L-series breath testers (LX9, LT7) certified to AS 3547:2019; driving market penetration."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-26-000377","json":"https://secwatch.observer/filing/0001079973-26-000377.json","markdown":"https://secwatch.observer/filing/0001079973-26-000377.md","text":"https://secwatch.observer/filing/0001079973-26-000377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1493137/000107997326000377/0001079973-26-000377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1493137/000107997326000377/lctc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:36:34.197101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4db87e2f8ccee2046142a64633955c8e8142681d","claim":"Lifeloc Technologies, Inc reported year ended December 31, 2025 results: revenue $9.027 million, net income ($2.470) million, EPS ($0.90) per diluted share.","evidence_excerpt":"devices, has announced financial results for the 2025 fiscal year ended December 31, 2025. 2025 Financial Highlights Lifeloc Technologies reported revenue growth of 6% to $9.027 million for 2025, compared to net revenue of $8.538 million for 2024. We realized a net loss of ($2.470) million , or ($0.90) per diluted share for the year ending December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1493137/000107997326000377/0001079973-26-000377-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Revenue","value":"$9.027 million"},{"label":"Net income","value":"($2.470) million"},{"label":"EPS","value":"($0.90) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}